Sector News

Amgen appoints senior VP and head of the European region

June 16, 2015
Life sciences
Amgen has named Corinne Le Goff as senior vice president and head of the European region.
 
Effective from June 1, Le Goff will be responsible for leading Amgen’s growth in Europe and will report directly to executive VP of global commercial operations, Anthony Hooper.
 
Commenting on her appointment, Le Goff said: “This is a pivotal moment for Amgen with a number of innovative new compounds either in the late stage clinical research or under review by the European regulatory authorities. 
 
“I am delighted to have the opportunity to lead the team in Europe at this exciting time.”
 
Le Goff joins from Roche, where she most recently served as president since 2012. In the role, she successfully led the business and a team of over 1,200 staff and helped evolve the business into one with a greater focus on market access and key account management.
 
Previously, Le Goff spent five years in strategic commercial leadership roles managing therapeutic areas at Roche, where she was senior VP of global product strategy for the neurosciences franchise and at Merck Serono, where she was senior VP of strategy and global marketing for neurology, rheumatology and immunology.
 
Hooper added: “Corinne brings strong vision and leadership to our European operations based on her broad strategic and operational experience in large healthcare organisations at both the global and affiliate level. I am delighted to welcome her to the team”.
 
Source: Amgen

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend